Kisspeptin

Kisspeptin (encoded by the KISS1 gene) is a family of endogenous neuropeptides that activate the kisspeptin receptor (KISS1R, also called GPR54). The peptide family includes kisspeptin-54 (the parent form, 54 amino acids) and shorter active fragments including kisspeptin-10 (the most pharmacologically active fragment). Kisspeptin is the key endogenous activator of the hypothalamic-pituitary-gonadal axis and is required for puberty, fertility, and reproductive function. Synthetic kisspeptin is administered intravenously or subcutaneously in research and clinical-trial settings.

The KISS1 gene was originally identified in 1996 as a metastasis suppressor gene in melanoma (the name derives from Hershey, Pennsylvania, where the gene was discovered, with "KISS" referencing Hershey Kisses). Its role in reproduction was discovered in 2003 when KISS1R mutations were identified as the cause of hypogonadotropic hypogonadism in patients with delayed puberty. The recognition that kisspeptin is the master regulator of the GnRH pulse generator transformed reproductive endocrinology.

The endogenous kisspeptin system consists of kisspeptin-expressing neurons primarily in the hypothalamic arcuate nucleus (which co-express neurokinin B and dynorphin, forming "KNDy neurons") and the anteroventral periventricular nucleus. These neurons project to GnRH neurons and drive the pulsatile GnRH secretion that controls LH and FSH release from the pituitary, which in turn controls gonadal hormone production and gametogenesis.

Synthetic kisspeptin-10 and kisspeptin-54 have been studied in clinical trials by Waljit Dhillo's group at Imperial College London for over a decade. The translational program has produced data across fertility treatment, functional hypothalamic amenorrhea, sexual desire disorders, and puberty disorders.

The HSDD Trials

The most prominent recent kisspeptin trials are the two HSDD studies by Dhillo's group.

Mills et al., JAMA Network Open, 2023 (men). Double-blind, 2-way crossover, placebo-controlled randomized trial in 32 men with HSDD. Participants received intravenous kisspeptin-54 (1 nmol/kg/h for 75 minutes) or placebo at separate visits. Primary outcomes included whole-brain fMRI activity in response to sexual stimuli, penile tumescence, and behavioral measures of sexual desire.

Kisspeptin administration produced significant changes in brain activity patterns during sexual stimuli compared with placebo. Penile tumescence was enhanced. Behavioral measures showed dose-related improvements in sexual desire and arousal. The trial established proof of concept for kisspeptin in male HSDD, which currently has no FDA-approved pharmacologic treatment.

Thurston et al., JAMA Network Open, 2022 (women). Double-blind, 2-way crossover, placebo-controlled randomized trial in 32 premenopausal women with HSDD. Kisspeptin-54 infusion at 1 nmol/kg/h for 75 minutes. Outcomes included brain processing of erotic and attraction stimuli on fMRI, psychometric questionnaires, and hormonal analyses.

Kisspeptin modulated sexual and attraction brain processing in functional neuroimaging, psychometric analyses, and hormonal measures. Modulation of brain processing correlated with psychometric measures of sexual aversion and associated distress. The findings established the foundation for further clinical development in female HSDD.

For perspective, the only FDA-approved pharmacologic treatment for female HSDD is bremelanotide (Vyleesi), with a different mechanism (melanocortin receptor agonism). Male HSDD currently has no approved pharmacologic treatment despite affecting approximately 8 percent of men.

Other Kisspeptin Clinical Applications

The kisspeptin clinical development program spans multiple indications.

IVF trigger for oocyte maturation. Kisspeptin-54 can replace or supplement human chorionic gonadotropin (hCG) as a trigger for oocyte maturation during in vitro fertilization. The advantages compared with hCG include reduced risk of ovarian hyperstimulation syndrome (OHSS) and more physiological LH surge dynamics. Multiple Phase 2 trials by the Imperial College group have established kisspeptin-54 as a viable trigger agent, particularly in high-OHSS-risk patients.

Functional hypothalamic amenorrhea. Women with stress, weight loss, or excessive exercise can develop hypothalamic amenorrhea due to suppressed kisspeptin-GnRH pulse generation. Kisspeptin administration can restore pulsatile GnRH and gonadotropin secretion in these patients. Phase 2 trials have shown this restoration, though chronic dosing for fertility recovery has not yet been established.

Diagnostic test for hypogonadotropic hypogonadism. Kisspeptin-10 stimulation testing can distinguish between hypothalamic deficiency (kisspeptin response preserved, GnRH neurons intact) and primary GnRH neuron absence (kisspeptin response absent). This is mechanistic diagnostic information beyond standard hormone panels.

Pubertal disorder evaluation. Kisspeptin stimulation can assess pituitary GnRH response in patients with delayed or precocious puberty, providing more informative data than standard gonadotropin measurements alone.

Osteoporosis. Preclinical work has explored kisspeptin's effects on bone metabolism, though this indication is at an earlier development stage than the reproductive applications.

Kisspeptin acts on KISS1R receptors in multiple anatomical regions, producing distinct clinical effects depending on location.

Hypothalamic effects: GnRH pulse generator activation. Kisspeptin binding to KISS1R on GnRH neurons triggers pulsatile GnRH release. The downstream cascade leads to LH and FSH secretion from the pituitary, then to gonadal steroidogenesis (testosterone in men, estradiol and progesterone in women) and gametogenesis. This is the canonical kisspeptin function and the basis for fertility-related applications.

Limbic and brain region effects: sexual processing. KISS1R is also expressed in limbic brain regions involved in sexual behavior, reward, and emotional processing. Kisspeptin administration modulates brain activity in these regions in response to sexual stimuli, which is the basis for the HSDD applications.

Direct effects on gonadotropin secretion. Beyond pulse generation, kisspeptin has direct dose-dependent effects on LH release that can be exploited therapeutically. The dose-response curve for LH stimulation is steep, which makes kisspeptin useful as a "trigger" for oocyte maturation in IVF (replacing or supplementing hCG).

Peripheral effects. Kisspeptin is also expressed in peripheral tissues including placenta, ovary, and pancreas, with proposed roles in implantation, ovarian function, and possibly metabolic regulation.

The pharmacokinetic profile is shaped by enzymatic degradation. Kisspeptin-10 has a plasma half-life of approximately 30 minutes when administered intravenously. Subcutaneous administration produces a longer effective profile. The peptide is too short and degradation-prone for oral administration.

Regulatory status

Kisspeptin currently has no FDA approval, no EMA approval, and no marketing authorization in any country for any indication. Despite the substantial Phase 2 clinical-trial program, no Phase 3 registrational program has been completed for any specific indication.

The most likely first regulatory approval would be in IVF triggering for high-OHSS-risk patients, where the safety advantage over hCG is clearly defined and the indication has a clear patient population. Phase 3 trials in this indication are anticipated but timeline depends on sponsor commitments that have not been finalized.

The HSDD applications would require larger Phase 3 trials with patient-reported outcome measures that have not yet been completed at registrational scale.

The compound is not on the FDA Category 2 bulks list as of May 2026. Compounding pharmacy availability is limited and varies by individual practice. Some research-chemical vendors sell kisspeptin-10 with "for laboratory use only" labeling.

WADA status. Kisspeptin is on the WADA Prohibited List under section S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics) as a "gonadotropin-releasing factor" that triggers LH and FSH release. Use in competitive sport is a doping violation.

Dosing protocols and literature-reported ranges are documented in the approved label or trial publications referenced above.

The Phase 2 clinical-trial dataset across more than 200 patients reports a generally clean safety profile.

Mild flushing and warmth during infusion in some patients, related to the dose-dependent LH surge.

Mild nausea at higher doses.

No serious adverse events have been reported in the published trials at the doses used. Kisspeptin is an endogenous peptide and the synthetic form is well-tolerated.

Theoretical considerations. As a gonadotropin-stimulating peptide, kisspeptin's safety profile in patients with hormone-sensitive cancers (breast, prostate, endometrial) has not been characterized at chronic dosing. Pregnancy and pediatric data is limited to specific clinical trial settings.

The Phase 2 trial program has built a solid safety foundation for the IVF and short-term HSDD indications. Long-term safety with chronic dosing has not been established for any indication.

The most relevant comparisons are within the sexual-dysfunction space.

Bremelanotide (PT-141, Vyleesi) is the only FDA-approved drug for female HSDD. It works on melanocortin receptors centrally. The mechanism is different from kisspeptin. PT-141 has a documented but limited efficacy profile and substantial gastrointestinal side effects.

Flibanserin (Addyi) is another approved drug for premenopausal HSDD. It works on serotonin and dopamine systems with daily oral dosing. Effects build over weeks. The side-effect profile includes alcohol interaction warnings.

PDE5 inhibitors (sildenafil, tadalafil) are FDA-approved for male erectile dysfunction. They work on peripheral vasodilation rather than central desire. They are not approved for women and do not address the central drive component that kisspeptin targets.

For HSDD specifically, kisspeptin would represent a mechanistically different approach: central activation of reproductive and sexual processing circuits via the endogenous reproductive neuropeptide system. Whether this translates to superior clinical outcomes versus the existing approved drugs requires Phase 3 trials that have not been completed.